

I welcome the recognition by you and the rest of the board of the need to explore options for the future of VMIC.

Your request for support from UKRI and VTF is noted, and we are already working at pace to bring together a team and external advisors. Whilst we are conscious of the urgency, please allow my team a few days to explore the options, update ministers, and articulate a plan to progress this matter.

In the meantime, I remain available if you have any questions.

Tim



Tim Cullen

Vaccines Taskforce – Onshoring Programme Director (Acting)

Irrelevant & Sensitive

1 Victoria Street, London, SW1H 0ET

tim.cullen@beis.gov.uk

www.gov.uk/beis | <https://twitter.com/beisgovuk>

PA: **Name Redacted** [@beis.gov.uk](mailto:Name Redacted@beis.gov.uk)

Within the VTF we work flexibly - it suits me to email you now, but I do not expect a response or action outside your own working hours.

From: Shattock, Robin J <r.shattock@imperial.ac.uk>

Sent: 03 October 2021 13:32

To: Andy Jones - UKRI INNOVATEUK <andy.jones@innovateuk.ukri.org>

Cc: Cullen, Tim (Vaccines Taskforce Onshoring Directorate) <Tim.cullen@beis.gov.uk>

Subject: Sustainability of VMIC

3rd October 2021

To Andy Jones

ISCF Medicines Manufacturing Challenge Director

Innovate UK

UKRI, Polaris House, North Star Avenue, Swindon, SN2 1FL

Dear Andy Jones,

I am writing to you on behalf of the Board of Directors to request permission for the VMIC board to explore various strategic options to secure the sustainable future of the VMIC facility. I am also requesting the support of UKRI and the VTF to help with this exploration and utilise their extensive relationships to secure successful deals.

As you are aware, there has been a significant shift in the vaccines manufacturing market. When we received extra funding from BEIS and the Vaccine Taskforce in early 2020 we were asked to develop our manufacturing capability to deliver Covid-19 vaccines by the Winter of 2021. This goal was to provide, in addition to the innovation focus, a surge capacity of some 70m vaccine doses in the current and any future pandemic crisis. Since this investment we have all been surprised by the market response. There are now multiple approved vaccines and investment in vaccine infrastructure in the UK is growing. The UK is now in a much more resilient position than when the investment decision was made.

At the same time the supply of labour and building materials has been constrained which has significantly impacted the outturn costs of the development. In order to complete the development, we would need significant further funding,